Skip to content

Trial · Interventional

CompletedPhase 2Registry data

Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

NCTNCT00184652 (opens ClinicalTrials.gov in a new tab)Other idNN1606-1442
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 2
Enrollment
140 participants (actual)
Sponsor
Novo Nordisk A/S · Industry
Design
Randomized · Double masking
Countries
9 countries

Denmark, Germany, Hong Kong, Israel, Poland, Singapore, Sweden, Switzerland, United Kingdom

Start
Apr 2003
Primary completion
Sept 2005
Completion
Sept 2005
First posted
16 Sept 2005 (estimated)
Last update posted
24 Jan 2017 (estimated)
Conditions
Chronic Kidney Disease · End-Stage Renal Disease

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2003200420052006
  1. Ph 2

    Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

    NCT00184652

    Apr 2003 to Sept 2005

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney disease are treated with growth hormone to assess effect on nutritional status.

Interventions

  • somatropinDrug

Arms0

The registry lists no arms for this trial.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change in surrogate markers of nutrition

    Time frame · After 6 months treatment

Secondary outcomes(2)

  1. Quality of Life

  2. Other markers of nutrition

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2007

8 results

Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk.

Feldt-Rasmussen et al. 2007Journal of the American Society of Nephrology : JASNcited by 77

PMID 17554147DOI 10.1681/asn.2006111207PUB-17554147

Rights unknown8 results
Source linkSee results (8)

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 99 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * ESRD patients Exclusion Criteria: * Diabetes Mellitus * Severe and Malignant diseases * Patients in Intensive Care Units

PepBank is a research reference. Talk to a doctor before you use any peptide.